NPHLA Tracker · GLP-1 & obesity drug pipeline (ClinicalTrials.gov)
GLP-1 & Obesity Drug Pipeline
Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 181
- Changed in 7 days
- 4
- Latest record
- Jurisdiction
- International / multiple
Records
4 changed in the last 7 daysInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| A Study of BGM0504 in Participants With Type 2 DiabetesNCT06716216Changed in the last 7 days Status changed from “Active, not recruiting” to “Completed” · Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC | Completed | Phase 3 | BrightGene Bio-Medical Technology Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06716216 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792Changed in the last 7 days Status changed from “Not yet recruiting” to “Recruiting” · Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC) | Recruiting | Phase 2 / Phase 3 | yifang zhu | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07734792 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872Changed in the last 7 days Status changed from “Active, not recruiting” to “Recruiting” · Conditions: Type 2 Diabetes Mellitus. Interventions: Tifeglipron; Semaglutide; Placebo | Recruiting | Phase 2 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07112872 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151Changed in the last 7 days Results first posted on ClinicalTrials.gov (2026-11-09) · Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo | Completed | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05936151 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.
When a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.
What does it cover?
Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.
What are its limitations?
Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.